Risk Factors, Management, and Outcome of Gastric Venous Congestion After Total Pancreatectomy: An Underestimated Complication Requiring Standardized Identification, Grading, and Management.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
28
03
2023
accepted:
19
06
2023
medline:
12
10
2023
pubmed:
19
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
Gastric venous congestion (GVC) after total pancreatectomy (TP) is rarely studied despite its high 5% to 28% incidence and possible association with mortality. This study aimed to provide insight about incidence, risk factors, management, and outcome of GVC after TP. This retrospective observational single-center study included all patients undergoing elective TP from 2008 to 2021. The exclusion criteria ruled out a history of gastric resection, concomitant (sub)total gastrectomy for oncologic indication(s) or celiac axis resection, and postoperative (sub)total gastrectomy for indication(s) other than GVC. The study enrolled 268 patients. The in-hospital major morbidity (Clavien-Dindo grade ≥IIIa) rate was 28%, and the 90-day mortality rate was 3%. GVC was identified in 21% of patients, particularly occurring during index surgery (93%). Intraoperative GVC was managed with (sub)total gastrectomy for 55% of the patients. The major morbidity rate was higher for the patients with GVC (44% vs 24%; p = 0.003), whereas the 90-day mortality did not differ significantly (5% vs 3%; p = 0.406). The predictors for major morbidity were intraoperative GVC (odds ratio [OR], 2.207; 95% confidence interval [CI], 1.142-4.268) and high TP volume (> 20 TPs/year: OR, 0.360; 95% CI, 0.175-0.738). The predictors for GVC were portomesenteric venous resection (PVR) (OR, 2.103; 95% CI, 1.034-4.278) and left coronary vein ligation (OR, 11.858; 95% CI, 5.772-24.362). After TP, GVC is rather common (in 1 of 5 patients). GVC during index surgery is predictive for major morbidity, although not translating into higher mortality. Left coronary vein ligation and PVR are predictive for GVC, requiring vigilance during and after surgery, although gastric resection is not always necessary. More evidence on prevention, identification, classification, and management of GVC is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Gastric venous congestion (GVC) after total pancreatectomy (TP) is rarely studied despite its high 5% to 28% incidence and possible association with mortality. This study aimed to provide insight about incidence, risk factors, management, and outcome of GVC after TP.
METHODS
METHODS
This retrospective observational single-center study included all patients undergoing elective TP from 2008 to 2021. The exclusion criteria ruled out a history of gastric resection, concomitant (sub)total gastrectomy for oncologic indication(s) or celiac axis resection, and postoperative (sub)total gastrectomy for indication(s) other than GVC.
RESULTS
RESULTS
The study enrolled 268 patients. The in-hospital major morbidity (Clavien-Dindo grade ≥IIIa) rate was 28%, and the 90-day mortality rate was 3%. GVC was identified in 21% of patients, particularly occurring during index surgery (93%). Intraoperative GVC was managed with (sub)total gastrectomy for 55% of the patients. The major morbidity rate was higher for the patients with GVC (44% vs 24%; p = 0.003), whereas the 90-day mortality did not differ significantly (5% vs 3%; p = 0.406). The predictors for major morbidity were intraoperative GVC (odds ratio [OR], 2.207; 95% confidence interval [CI], 1.142-4.268) and high TP volume (> 20 TPs/year: OR, 0.360; 95% CI, 0.175-0.738). The predictors for GVC were portomesenteric venous resection (PVR) (OR, 2.103; 95% CI, 1.034-4.278) and left coronary vein ligation (OR, 11.858; 95% CI, 5.772-24.362).
CONCLUSIONS
CONCLUSIONS
After TP, GVC is rather common (in 1 of 5 patients). GVC during index surgery is predictive for major morbidity, although not translating into higher mortality. Left coronary vein ligation and PVR are predictive for GVC, requiring vigilance during and after surgery, although gastric resection is not always necessary. More evidence on prevention, identification, classification, and management of GVC is needed.
Identifiants
pubmed: 37596448
doi: 10.1245/s10434-023-13847-z
pii: 10.1245/s10434-023-13847-z
pmc: PMC10562271
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7700-7711Informations de copyright
© 2023. The Author(s).
Références
Br J Surg. 2021 Jul 23;108(7):777-785
pubmed: 34046668
Surgery. 2011 May;149(5):680-8
pubmed: 21316725
Langenbecks Arch Surg. 2021 Nov;406(7):2535-2543
pubmed: 34618219
J Hepatobiliary Pancreat Sci. 2018 Feb;25(2):150-154
pubmed: 29143477
Surgery. 2007 Nov;142(5):761-8
pubmed: 17981197
Ann Surg Oncol. 2023 Jul;30(7):4417-4428
pubmed: 37020094
Br J Surg. 2019 Dec;106(13):1735-1746
pubmed: 31502658
Ann Surg Oncol. 2021 Mar;28(3):1543-1551
pubmed: 32761326
J Gastrointest Oncol. 2021 Oct;12(5):2495-2502
pubmed: 34790410
Updates Surg. 2021 Aug;73(4):1205-1217
pubmed: 34390466
Surgery. 2014 Jul;156(1):1-14
pubmed: 24856668
BMC Surg. 2020 Feb 10;20(1):28
pubmed: 32041579
JAMA Surg. 2022 Feb 1;157(2):120-128
pubmed: 34787667
HPB (Oxford). 2012 Jun;14(6):414-21
pubmed: 22568419
Biochem Med (Zagreb). 2014 Feb 15;24(1):12-8
pubmed: 24627710
Pancreas. 2020 Feb;49(2):175-180
pubmed: 32011524
Br J Surg. 2022 Dec 13;110(1):34-42
pubmed: 36346716
J Hepatobiliary Pancreat Sci. 2022 Apr;29(4):428-438
pubmed: 34863034
Ann Surg. 2022 Dec 1;276(6):e896-e904
pubmed: 33914472
Langenbecks Arch Surg. 2022 Dec;407(8):3457-3465
pubmed: 36169725
Ann Surg. 2023 Oct 1;278(4):e702-e711
pubmed: 37161977
Gastric Cancer. 2018 May;21(3):524-532
pubmed: 29067597
J Gastrointest Surg. 2010 Jun;14(6):1027-30
pubmed: 20387128
Hepatogastroenterology. 2011 Jan-Feb;58(105):198-201
pubmed: 21510314
Surgery. 2007 Jul;142(1):20-5
pubmed: 17629996
Surgery. 2014 Jun;155(6):977-88
pubmed: 24856119
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
HPB (Oxford). 2013 Nov;15(11):882-92
pubmed: 23458647
HPB (Oxford). 2015 Apr;17(4):368-70
pubmed: 25059096
Surgery. 2021 Aug;170(2):563-570
pubmed: 33741182
Scand J Surg. 2020 Mar;109(1):18-28
pubmed: 31960765
Ann Surg Oncol. 2020 Feb;27(2):587-596
pubmed: 31562603
Surgery. 2020 Dec;168(6):1048-1055
pubmed: 32951905
Medicine (Baltimore). 2022 Sep 9;101(36):e30390
pubmed: 36086699
Surgery. 2022 Sep;172(3):962-967
pubmed: 35820975
Ann Surg Oncol. 2021 Jan;28(1):48-56
pubmed: 33125569
Updates Surg. 2016 Sep;68(3):257-263
pubmed: 27605208
Cancer Manag Res. 2019 May 07;11:3899-3908
pubmed: 31123419
Ann Surg. 2009 Aug;250(2):187-96
pubmed: 19638912
Ann Surg. 2022 Dec 1;276(6):e905-e913
pubmed: 33914471
Br J Surg. 2016 Nov;103(12):1683-1694
pubmed: 27686238
HPB (Oxford). 2022 Aug;24(8):1261-1270
pubmed: 35031280
Ann Surg. 2022 Nov 1;276(5):e536-e543
pubmed: 33177356
BMJ Open. 2021 Oct 21;11(10):e052745
pubmed: 34675020